[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2136618T3 - Cicatrizacion de heridas. - Google Patents

Cicatrizacion de heridas.

Info

Publication number
ES2136618T3
ES2136618T3 ES92907214T ES92907214T ES2136618T3 ES 2136618 T3 ES2136618 T3 ES 2136618T3 ES 92907214 T ES92907214 T ES 92907214T ES 92907214 T ES92907214 T ES 92907214T ES 2136618 T3 ES2136618 T3 ES 2136618T3
Authority
ES
Spain
Prior art keywords
composition
presented
wound healing
agent
wounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92907214T
Other languages
English (en)
Other versions
ES2136618T5 (es
Inventor
Mark W J Ferguson
David M Foreman
Mamta Shah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Victoria University of Manchester
University of Manchester
Original Assignee
Victoria University of Manchester
University of Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10692386&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2136618(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Victoria University of Manchester, University of Manchester filed Critical Victoria University of Manchester
Publication of ES2136618T3 publication Critical patent/ES2136618T3/es
Application granted granted Critical
Publication of ES2136618T5 publication Critical patent/ES2136618T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Transceivers (AREA)
  • Mobile Radio Communication Systems (AREA)

Abstract

SE PRESENTA UNA COMPOSICION PARA UTILIZAR EN EL TRATAMIENTO DE HERIDAS PARA INHIBIR LA FORMACION DE TEJIDO DE CICATRIZ DURANTE LA CICATRIZACION, QUE COMPRENDE UNA CANTIDAD DE INHIBICION DE ACTIVIDAD EFECTIVA DE UN AGENTE DE NEUTRALIZACION DE FACTOR DE CRECIMIENTO O AGENTES ESPECIFICOS CONTRA SOLO FACTORES DE CRECIMIENTO FIBROTICOS JUNTO CON UN PORTADOR FARMACEUTICAMENTE ACEPTABLE. TAMBIEN SE PRESENTA EL METODO DE PREPARACION DE DICHA COMPOSICION Y METODO DE ADMINISTRACION DE LA COMPOSICION A UN PACIENTE QUE SUFRE DE HERIDAS EN LOS TEJIDOS.
ES92907214T 1991-03-28 1992-03-30 Curacion de heridas. Expired - Lifetime ES2136618T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919106678A GB9106678D0 (en) 1991-03-28 1991-03-28 Wound healing
GB9106678 1991-03-28

Publications (2)

Publication Number Publication Date
ES2136618T3 true ES2136618T3 (es) 1999-12-01
ES2136618T5 ES2136618T5 (es) 2007-10-16

Family

ID=10692386

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92907214T Expired - Lifetime ES2136618T5 (es) 1991-03-28 1992-03-30 Curacion de heridas.

Country Status (13)

Country Link
US (4) US5662904A (es)
EP (1) EP0585242B2 (es)
JP (3) JP3333507B2 (es)
AT (1) ATE182792T1 (es)
AU (1) AU661840B2 (es)
CA (2) CA2387247C (es)
DE (1) DE69229729T3 (es)
DK (1) DK0585242T4 (es)
ES (1) ES2136618T5 (es)
GB (1) GB9106678D0 (es)
GR (1) GR3030924T3 (es)
IE (1) IE921013A1 (es)
WO (1) WO1992017206A1 (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654270A (en) 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
US5571714A (en) * 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5177197A (en) * 1990-02-27 1993-01-05 Ludwig Institute For Cancer Research Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
US6117425A (en) 1990-11-27 2000-09-12 The American National Red Cross Supplemented and unsupplemented tissue sealants, method of their production and use
US6197325B1 (en) 1990-11-27 2001-03-06 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US6054122A (en) 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US7229959B1 (en) * 1990-11-27 2007-06-12 The American National Red Cross Supplemented fibrin matrix delivery systems
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
DE69232946T2 (de) * 1991-11-14 2003-12-18 La Jolla Cancer Research Foundation, La Jolla Inhibitoren von zellregulationsfaktoren und verfahren zur verhütung oder verminderung von narbenbildung
WO1993014782A1 (en) * 1992-01-29 1993-08-05 La Jolla Cancer Research Foundation Methods of controlling the proliferation of macrophages
GB9205800D0 (en) * 1992-03-17 1992-04-29 British Tech Group Treatment of fibrotic disorders
GB9206861D0 (en) * 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
AU4769893A (en) * 1992-07-17 1994-02-14 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of animal diseases
ES2174868T3 (es) * 1992-10-29 2002-11-16 Celtrix Pharma Fragmento del receptor de fijacion a tgf-beta tipoii como agente terapeutico.
WO1994029452A2 (en) * 1993-06-09 1994-12-22 Ribozyme Pharmaceuticals, Inc. Enzymatic rna molecules and their application in the treatment of fibrosis and fibrous tissue disease
WO1995000103A2 (en) * 1993-06-15 1995-01-05 Il-Yang Pharm. Co., Ltd. Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
WO1995013827A1 (en) * 1993-11-19 1995-05-26 The University Of Sydney A method for preventing or controlling cataract
WO1995016032A1 (en) * 1993-12-09 1995-06-15 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH ANTISENSE NUCLEIC ACID FOR THE TREATMENT OF DISEASES IN WHICH EXPRESSION OF bFGF, PDGF-A OR PDGF-B PLAYS A PATHOGENIC ROLE
EP0750503A4 (en) * 1994-03-07 1999-07-21 Immusol Inc RIBOZYME-BASED THERAPY TO TREAT RESTENOSIS
US5834440A (en) * 1994-03-07 1998-11-10 Immusol Incorporated Ribozyme therapy for the inhibition of restenosis
GB9405046D0 (en) * 1994-03-15 1994-04-27 Unilever Plc Skin treatment composition
GB2288118A (en) * 1994-03-29 1995-10-11 Univ Manchester Wound healing composition
ATE186220T1 (de) * 1994-03-29 1999-11-15 Univ Manchester Wundheilung
US5824655A (en) * 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
GB2304045A (en) * 1995-08-04 1997-03-12 Univ Manchester Betaglycan compositions for promoting the healing of wounds and fibrotic diseases
GB2304047A (en) * 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
US7368111B2 (en) * 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
GB9601081D0 (en) * 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
GB2306481A (en) * 1995-10-21 1997-05-07 Univ Manchester Pharmaceutical comprising a stimulator of activin and/or inhibin
GB9702943D0 (en) * 1997-02-13 1997-04-02 Univ Manchester Wound healing
AU9294698A (en) * 1997-08-27 1999-03-16 Beth Israel Deaconess Hospital Corp. Methods and compositions for enhanced wound healing
US6444657B1 (en) 1998-12-31 2002-09-03 Guilford Pharmaceuticals Inc. Methods for treating certain diseases using naaladase inhibitors
US6410519B1 (en) * 1999-03-04 2002-06-25 United States Surgical Corporation Scar reduction
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
US6630142B2 (en) 1999-05-03 2003-10-07 Zymogenetics, Inc. Method of treating fibroproliferative disorders
US7261881B1 (en) 1999-05-20 2007-08-28 Yale University Modulation of angiogenesis and wound healing
AU7686400A (en) * 1999-10-15 2001-04-23 Nihon University, School Juridical Person Ribozymes to growth factor originating in human platelet
US6893637B1 (en) 1999-10-21 2005-05-17 Zymogenetics, Inc. Method of treating fibrosis
US20040197333A1 (en) * 2000-02-10 2004-10-07 Cornell Research Foundation, Inc. Use of TGF-beta antagonists to inhibit tumor cell formation or progression
AU9407501A (en) * 2000-06-23 2002-04-22 Medigenes Agent for reduction of scar formation by using wound alkalinization
US6509318B1 (en) 2000-09-29 2003-01-21 The Regents Of The University Of California TGF-B inhibitors and methods
DE60142632D1 (de) * 2000-11-30 2010-09-02 Novodermix Internat Ltd Heilung von wunden
US20040235791A1 (en) * 2002-01-25 2004-11-25 Gruskin Elliott A. Scar reduction
GB0217136D0 (en) 2002-07-24 2002-09-04 Renovo Ltd Wound healing & treatment of fibrosis
GB0309064D0 (en) 2003-04-22 2003-05-28 Univ Manchester Modified peptides and their uses
CA2903196A1 (en) 2003-08-27 2005-03-10 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
JP2007516742A (ja) * 2003-11-20 2007-06-28 アンジオテック インターナショナル アーゲー 電気装置と瘢痕化抑制剤
ZA200608130B (en) * 2004-03-31 2008-12-31 Genentech Inc Humanized anti-TGF-beta antibodies
DE102004025881A1 (de) * 2004-05-19 2006-01-05 Beiersdorf Ag Oligoribonukleotide zur Beeinflussung des Haarwachstums
US20070275874A1 (en) * 2004-09-03 2007-11-29 Yale University Use of Leptin in Wound Healing
US8109981B2 (en) 2005-01-25 2012-02-07 Valam Corporation Optical therapies and devices
US8574571B2 (en) * 2005-10-25 2013-11-05 Womens & Childrens Health Research Institute Methods and compositions for modulating wound repair
US8353881B2 (en) 2005-12-28 2013-01-15 Abbott Diabetes Care Inc. Infusion sets for the delivery of a therapeutic substance to a patient
US7981034B2 (en) 2006-02-28 2011-07-19 Abbott Diabetes Care Inc. Smart messages and alerts for an infusion delivery and management system
US9119582B2 (en) 2006-06-30 2015-09-01 Abbott Diabetes Care, Inc. Integrated analyte sensor and infusion device and methods therefor
US8932216B2 (en) 2006-08-07 2015-01-13 Abbott Diabetes Care Inc. Method and system for providing data management in integrated analyte monitoring and infusion system
US8206296B2 (en) 2006-08-07 2012-06-26 Abbott Diabetes Care Inc. Method and system for providing integrated analyte monitoring and infusion system therapy management
US8641618B2 (en) 2007-06-27 2014-02-04 Abbott Diabetes Care Inc. Method and structure for securing a monitoring device element
US8085151B2 (en) 2007-06-28 2011-12-27 Abbott Diabetes Care Inc. Signal converting cradle for medical condition monitoring and management system
CA2741028A1 (en) * 2008-10-21 2010-04-29 Novodermix International Limited Composition for treatment of epithelial tissue
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
EP2401614A1 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
CN116655801A (zh) 2013-08-22 2023-08-29 阿塞勒隆制药公司 TGF-β受体II型变体及其用途
CN116327952A (zh) 2015-08-04 2023-06-27 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法
EP4241848A3 (en) 2017-05-04 2023-11-01 Acceleron Pharma Inc. Tgf-beta receptor type ii fusion proteins and uses thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145676A (en) * 1981-09-08 1992-09-08 The Rockefeller University Method and agents for promoting wound healing
US5104977A (en) * 1982-09-24 1992-04-14 The United States Of America As Represented By The Department Of Health And Human Services Purified transforming growth factor beta
EP0105014B1 (en) * 1982-09-24 1992-05-20 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Repair of tissue in animals
CA1230591A (en) * 1983-06-03 1987-12-22 Charles A. Frolik PURIFIED TRANSFORMING GROWTH FACTOR-.beta. DERIVED FROM HUMAN PLATELETS AND PLACENTAS
DE3629640A1 (de) * 1986-08-30 1988-03-03 Behringwerke Ag Verwendung monoklonaler antikoerper zur therapie von tumoren
US4708948A (en) * 1984-04-20 1987-11-24 The United States Of America As Represented By The Department Of Health And Human Services Substantially purified tumor growth inhibitory factor
EP0169016B2 (en) * 1984-07-16 2004-04-28 Celtrix Pharmaceuticals, Inc. Polypeptide cartilage-inducing factors found in bone
IL78197A (en) * 1985-03-22 1991-07-18 Genentech Inc Nucleic acid encoding tgf-beta and its uses
US5168051A (en) * 1985-03-22 1992-12-01 Genentech, Inc. Nucleic acid encoding TGF-β its uses
US4886747A (en) * 1985-03-22 1989-12-12 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
IE60059B1 (en) * 1985-04-19 1994-05-18 Oncogene Science Inc Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
US5262319A (en) * 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
US4837381A (en) * 1986-08-11 1989-06-06 American Cyanamid Company Compositions for parenteral administration and their use
US4931548A (en) * 1987-01-30 1990-06-05 Techne Corporation Heterodimer form of transforming growth factor-beta
WO1988007057A1 (en) * 1987-03-13 1988-09-22 Amgen Inc. Purified platelet-derived growth factor and methods for purification thereof
EP0418234B1 (en) * 1988-06-08 1994-03-23 Genentech, Inc. NUCLEIC ACID ENCODING TGF-$g(b)3 AND ITS USE
US5055447A (en) * 1988-07-28 1991-10-08 Genentech, Inc. Method and compositions for the treatment and prevention of septic shock
GB8823649D0 (en) * 1988-10-07 1988-11-16 Geistlich Soehne Ag Chemical compounds
US5135915A (en) * 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
IE61346B1 (en) * 1988-11-02 1994-11-02 Genentech Inc A permeable material to fit around the teeth or gums of a mammal
CA2005120A1 (en) * 1988-12-15 1990-06-15 Anthony F. Purchio Tgf-beta 1/beta 2: a novel chimeric transforming growth factor-beta
US5118791A (en) * 1989-05-25 1992-06-02 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
US5061786A (en) * 1989-05-25 1991-10-29 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
EP0494264B1 (en) * 1989-09-29 1997-06-18 La Jolla Cancer Research Foundation Inhibiting transforming growth factor to prevent accumulation of extracellular matrix
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
WO1991010727A1 (en) * 1990-01-22 1991-07-25 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors
US5147854A (en) * 1990-05-22 1992-09-15 Hoffmann-La Roche Inc. Tgf-b compositions and method
JPH05509320A (ja) * 1990-06-25 1993-12-22 オーエスアイ　ファーマシューティカルズ，インコーポレイティド 組織誘導型腫瘍成長抑制物質、その調製及び使用方法
US5149801A (en) * 1990-11-21 1992-09-22 The Regents Of The University Of California Boronated porphyrin compounds
GB9101645D0 (en) * 1991-01-25 1991-03-06 British Bio Technology Compounds
AU1426792A (en) * 1991-02-04 1992-09-07 Oncogene Science, Inc. Inhibition of multidrug transport by transforming growth factor beta and uses thereof
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
CA2071137A1 (en) * 1991-07-10 1993-01-11 Clarence C. Lee Composition and method for revitalizing scar tissue
AU2738392A (en) * 1991-11-11 1993-05-13 Ciba-Geigy Ag Novel hybrid transforming growth factors
GB9205800D0 (en) * 1992-03-17 1992-04-29 British Tech Group Treatment of fibrotic disorders
GB9206861D0 (en) * 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
WO1995000103A2 (en) * 1993-06-15 1995-01-05 Il-Yang Pharm. Co., Ltd. Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
ATE186220T1 (de) * 1994-03-29 1999-11-15 Univ Manchester Wundheilung

Also Published As

Publication number Publication date
GR3030924T3 (en) 1999-11-30
US20100152095A1 (en) 2010-06-17
CA2387247A1 (en) 1992-10-15
EP0585242B1 (en) 1999-08-04
DE69229729T3 (de) 2007-10-18
EP0585242B2 (en) 2007-03-07
AU661840B2 (en) 1995-08-10
JP2006001949A (ja) 2006-01-05
IE921013A1 (en) 1992-10-07
US20050287139A1 (en) 2005-12-29
ATE182792T1 (de) 1999-08-15
US5662904A (en) 1997-09-02
JPH06506205A (ja) 1994-07-14
CA2387247C (en) 2009-05-19
GB9106678D0 (en) 1991-05-15
JP3333507B2 (ja) 2002-10-15
DK0585242T4 (da) 2007-07-02
JP2002275094A (ja) 2002-09-25
DK0585242T3 (da) 1999-12-06
US20020187149A1 (en) 2002-12-12
CA2105652C (en) 2005-09-06
WO1992017206A1 (en) 1992-10-15
DE69229729D1 (de) 1999-09-09
ES2136618T5 (es) 2007-10-16
CA2105652A1 (en) 1992-09-29
AU1436892A (en) 1992-11-02
EP0585242A1 (en) 1994-03-09
DE69229729T2 (de) 2000-01-13

Similar Documents

Publication Publication Date Title
ES2136618T3 (es) Cicatrizacion de heridas.
EP1736152A3 (en) Physiologically stable compositions of butyric acid as well as butyric acid salts and derivatives for treating wounds
AU546216B2 (en) Combined electronic and anesthetic pain control
ID24901A (id) Metode pengobatan keadaan terkoagulasi tinggi atau defisiensi protein c yang diperoleh
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
HU9300636D0 (en) Medical preparatives, method for producing them and their applications as analgetic and/or febrifuge in human and veterinary medicine
AR022090A1 (es) PARTíCULAS PARA LA ADMINISTRACIoN DE UN AGENTE ACTIVO A LOS ALVÉOLOS DE UN PACIENTE HUMANO, UN MÉTODO PARA SU PREPARACIoN, Y EL USO DE LAS MISMAS PARA LA PREPARACIoN DE UN MEDICAMENTO PARA INHALACIoN
ATE187649T1 (de) Verwendung des gewebefaktor-inhibitors zur herstellung eines arzneimittels gegen mikrogefässthrombose
EP0682521A4 (en) PROCESS FOR THE TREATMENT WITH MISOPROSTOL OF MUCUSUS AND EPITHELIAL TISSUES WITH LESIONS.
US4025645A (en) Non-steroid topical agent for alleviating inflammation in mammals
DK1009425T3 (da) Anvendelse af latens-associeret-peptid til fremstilling af et medikament til forøgelse af sårheling
ES2184145T3 (es) Compuestos de acido sulfonico o sulfonilamino-n-(heteroaralquil)-azaheterociclilamida.
ES2125696T3 (es) Utilizacion del cloruro de tropsio para la produccion de una preparacion farmaceutica para el tratamiento de disfunciones vesicales.
DK0484340T3 (da) Behandling til nedsættelse af ødem ved hjerne- og muskelbeskadigelser
SE9101840D0 (sv) New medicinal use
ES2138602T3 (es) Agente terapeutico para la amenaza de aborto.
Burgess et al. Tocopherol (vitamin E) therapy in sclerosis with ulcer
MY114716A (en) Prophylactic and/or therapeutic treatment of dyspeptic symptoms
ES2182840T3 (es) Factor xiii para el tratamiento de heridas de la piel.
Lipton et al. Streptococcus Viridans Septicemia-Subacute Bacterial Endarteritis of an Arteriovenous Aneurysm
Burke et al. Primary excision and prompt grafting as routine therapy for the treatment of thermal burns in children
Brown Bilateral Ainhum treated by multiple Z-plasties
SMITH Amputation through lower third of leg for diabetic and arteriosclerotic gangrene
BE894860A (fr) Therapeutique adjuvante par agent progestatif
Davis The effect of scarlet red, in various combinations, upon the epitheliation of granulating surfaces

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 585242

Country of ref document: ES